NEW YORK--(BUSINESS WIRE)--The Klein Law Firm announces that a class action complaint has been
filed on behalf of shareholders of Puma Biotechnology, Inc. (NASDAQ:
PBYI) who purchased shares between February 29,
2016 and May 4, 2017. The action,
which was Best Attorney College Station filed in the United States District Court for the Best Attorney Central
District of California, alleges that the Company violated federal
securities laws.
In particular, the complaint alleges that throughout the Class Period,
defendants made materially false and/or misleading statements and/or
failed to disclose that (i) the Company did not anticipate that the U.S.
Food and Drug Administration ("FDA") would ultimately approve PB272 < br>
("neratinib") for the treatment of breast cancer; (ii) as such, Puma
Biotechnology had overstated the drug's approval prospects and/or
commercial viability; and (iii) as a result, Puma Biotechnology's public
statements were materially false and misleading at all relevant times.
Shareholders have until July 7, 2017 to petition the court for
lead plaintiff status. Your ability to share in any recovery does not
require that you serve as lead plaintiff. You may choose to be an absent
class member.
If you suffered a loss during the class period and wish to obtain
additional information, please contact Joseph Klein, Esq. by telephone
at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/puma-biotechnology-inc?wire=2.
Joseph http://www.uscourts.gov/forms/attorney-forms Klein, Esq. is an experienced attorney and has also practiced as
a Certified Public Accountant. Mr. Klein represents investors and
participates in securities litigations involving financial fraud
throughout the nation. Attorney advertising. Prior results do not
guarantee similar outcomes.
http://www.businesswire.com/news/home/20170612005903/en/Klein-Law-Firm-Announces-Class-Action-Filed
No comments:
Post a Comment